Compare PTEN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTEN | ACAD |
|---|---|---|
| Founded | 1978 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.8B |
| IPO Year | 1995 | 2000 |
| Metric | PTEN | ACAD |
|---|---|---|
| Price | $12.26 | $21.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 22 |
| Target Price | $10.80 | ★ $30.55 |
| AVG Volume (30 Days) | ★ 7.7M | 1.6M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | ★ 90.16 | 69.12 |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $4,826,624,000.00 | $726,437,000.00 |
| Revenue This Year | N/A | $18.80 |
| Revenue Next Year | $4.34 | $11.70 |
| P/E Ratio | ★ N/A | $1,066.50 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $5.10 | $19.69 |
| 52 Week High | $13.08 | $28.35 |
| Indicator | PTEN | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 44.59 |
| Support Level | $5.31 | $20.06 |
| Resistance Level | $12.62 | $22.64 |
| Average True Range (ATR) | 0.52 | 0.80 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 57.75 | 29.60 |
Patterson-UTI Energy Inc is a Texas based provider of drilling and completion services to oil and natural gas exploration and production companies, offering contract drilling, integrated well completion, directional drilling services, and specialized drill bit solutions. The Company operates through three segments: Drilling Services, Completion Services, and Drilling Products. Drilling Services includes contract and directional drilling, Completion Services generates maximum revenue and includes hydraulic fracturing and related support services, and Drilling Products includes the manufacturing and distribution of drill bits. The Company operates in the United States, Canada, Colombia, and Other Countries, with the majority of revenue coming from the United States.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.